Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

Harmanpreet Kaur; Kathryn Corscadden; Jerry Ware; Maha Othman

doi:10.1160/TH16-04-0317

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2017; 117(03): 543-555
DOI: 10.1160/TH16-04-0317

Cellular Haemostasis and Platelets

Schattauer GmbH

Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

Authors

Harmanpreet Kaur

¹Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada
Kathryn Corscadden

¹Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada
Jerry Ware

²Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Maha Othman

¹Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada

³School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada

Abstract

Summary

Platelet defects due to hyper-responsive GPIbα causing enhanced VWF interaction, counter-intuitively result in bleeding rather than thrombosis. The historical explanation of platelet/VWF clearance fails to explain mechanisms of impaired haemostasis particularly in light of reported poor platelet binding to fibrinogen. This study aimed to evaluate the defects of platelets with hyper-responsive GPIbα and their contribution to impaired in vivo thrombosis. Using the PT-VWD mouse model, platelets from the hTg^G233V were compared to control hTg^WT mice. Platelets’ pro-coagulant capacity was evaluated using flowcytometry assessment of P-selectin and annexin V. Whole blood platelet aggregation in response to ADP, collagen and thrombin was tested. Clot kinetics using laser injury thrombosis model and the effect of GPIbα inhibition in vivo using 6B4; a monoclonal antibody, were evaluated. Thrombin-induced platelet P-selectin and PS exposure were significantly reduced in hTg^G233V compared to hTg^WT and not signifi-cantly different when compared to unstimulated platelets. The hTg^G233V platelets aggregated normally in response to collagen, and had a delayed response to ADP and thrombin, when compared to hTgWT platelets. Laser injury showed significant impairment of in vivo thrombus formation in hTg^G233V compared to hTg^WT mice. There was a significant lag in in vitro clot formation in turbidity assay but no impairment in thrombin generation was observed using thromboelastography. The in vivo inhibition of GPIbα facilitated new – unstable – clot formation but did not improve the lag. We conclude platelets with hyper-responsive GPIbα have complex intrinsic defects beyond the previously described mechanisms. Abnormal signalling through GPIbα and potential therapy using inhibitors require further investigations.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

GPIbα inhibition - platelet activation - thrombin - platelet bleeding disorders - hyperresponsive GPIbα

Volltext

Referenzen

References
1 Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Intern J Biochem Cell Biol 1997; 29: 91-105.
2 Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 1995; 21: 130-136.
3 Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 2009; 35: 233-241.
4 Grainick HR, Williams SB, McKeown LP. et al. Von Willebrand’s disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-1529.
5 De Marco L, Girolami A, Zimmerman TS. et al. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci USA 1985; 82: 7424-7428.
6 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscl Thromb Vasc Biol 2002; 22: 1381-1389.
7 Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
8 Lopez JA, Andrews RK, Afshar-Kharghan V. et al. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.
9 Othman M, Kaur H, Favaloro EJ. et al. Platelet Type von Willebrand Disease and Registry Report: Communication from the SSC of the ISTH. J Thromb Haemost 2016; 14: 411-414.
10 Maurer M, Mesters R, Schneppenheim R. et al. Platelet-type von Willebrand Disease: Diagnostic Challenges. Flaws and Pitfalls Experienced in the THROMKID Quality Project. Klin Paediatr 2015; 227: 131-136.
11 Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev 2011; 25: 147-153.
12 Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011; 37: 464-469.
13 Frontroth JP, Hepner M, Sciuccati G. et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010; 104: 1158-1165.
14 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-haemostasis coin?. Semin Thromb Hemost 2008; 34: 113-127.
15 Favaloro EJ, Patterson D, Denholm A. et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139: 623-626.
16 Suva LJ, Hartman E, Dilley JD. et al. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol 2008; 172: 430-439.
17 Guerrero JA, Kyei M, Russell S. et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood 2009; 114: 5541-5546.
18 Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-2808.
19 Cauwenberghs N, Meiring M, Vauterin S. et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscl Thromb Vasc Biol 2000; 20: 1347-1353.
20 Fontayne A, De Maeyer B, De Maeyer M. et al. Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem 2007; 282: 23517-23524.
21 Wu D, Meiring M, Kotze HF. et al. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscl Thromb Vasc Biol 2002; 22: 323-328.
22 Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-2478.
23 Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
24 Metassan S, Routledge MN, Lucking AJ. et al. Fibrin clot structure remains unaffected in young, healthy individuals after transient exposure to diesel exhaust. Particle Fibre Toxicol 2010; 07: 17.
25 Chou J, Mackman N, Merrill-Skoloff G. et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-3197.
26 Moos MP, Mewburn JD, Kan FW. et al. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 2008; 22: 4352-4362.
27 Nishimura S, Manabe I, Nagasaki M. et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signalling. Blood 2012; 119: e45-56.
28 Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-547.
29 Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004; 18: 172-177.
30 Ravanat C, Strassel C, Hechler B. et al. A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIbalpha N-terminal extracellular domain. Blood 2010; 116: 1157-1164.
31 Giannini S, Cecchetti L, Mezzasoma AM. et al. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010; 95: 1021-1024.
32 Sánchez-Luceros A, Woods AI, Bermejo E. et al. PT-VWD posing diagnostic and therapeutic challenges- small case series. Platelets 2016; 07: 1-7.
33 Fontayne A, Vanhoorelbeke K, Pareyn I. et al. Rational humanisation of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost 2006; 96: 671-684.
34 Andersen H, Greenberg DL, Fujikawa K. et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-11193.
35 Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42: 423-438.
36 Casari C, Berrou E, Lebret M. et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin alphaIIbbeta3. J Clin Invest 2013; 123: 5071-5081.
37 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142.
38 Dunn EJ, Philippou H, Ariens RA. et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
39 Carr Jr. ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. The J Lab Clin Med 1996; 128: 83-88.
40 Estevez B, Kim K, Delaney MK. et al. Signalling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 2016; 127: 626-636.
41 Alberio L, Dale GL. Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall. Br J Haematol 1998; 102: 1212-1218.
42 Bury L, Falcinelli E, Mezzasoma AM. et al. Defective alphaIIbbeta3 activation causes platelet dysfunction in von Willebrand disease platelet-type (PT-VWD). J Thromb Haemost 2015; 13 (Suppl. 02) 223.

Zusatzmaterial

Zusatzmaterial (PDF)